$THC

Foo Lisa Y sold $2.6M of THC

Foo Lisa Y (EVP, Chief Operating Officer) sold 10,000 shares of TENET HEALTHCARE CORP (THC) at $258.03 ($2.58M total) on 2026-07-29.

Original reporting
SEC EDGAR · Foo Lisa Y
Published Aug 1, 2026, 12:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 1, 2026, 12:03 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$THC
Neutral
medium confidence
Mentioned
$THC
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The newest fact is the specific sale details: 10,000 shares at $258.03, total value $2.58M, with holdings after sale of 32,053 shares, and no pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but there is no accompanying fundamental catalyst in the text.

03

What to watch

Insider sales can be driven by diversification, tax planning, or pre-existing personal liquidity needs; without additional context, the signal-to-noise is low.

Relevance 6/10Novelty 4/10Timing: Form 4 filed 2026-07-31, transaction dated 2026-07-29

Background

The article is an SEC Form 4 insider transaction disclosure for Tenet Healthcare, reporting an open-market sale by the COO.

Company-level read

Ticker impact

$THCNeutralMedium confidence
Context

Tenet Healthcare COO sold 10,000 shares in an open-market transaction at $258.03 on 2026-07-29, per Form 4 filed 2026-07-31.

Expected impact

Likely limited near-term impact; treat as low-signal unless paired with other disclosures or unusual volume.

Evidence & confidence

The filing discloses transaction size, price, and holdings, but provides no earnings, guidance, investigation, or deal catalyst. Insider sales are common and often non-informational, though the absence of a 10b5-1 plan slightly increases interpretive uncertainty.

Market effects

No clear sector read-through from a single insider sale at one healthcare services company.

None indicated.

None indicated.

Counterpoint

The lack of a 10b5-1 plan could reflect discretionary selling ahead of perceived risk, so some traders may front-run downside if they treat insider behavior as a leading indicator.

Key entities

  • Tenet Healthcare Corp

    Subject of the Form 4 insider transaction disclosure.

  • Foo Lisa Y

    EVP, Chief Operating Officer who sold shares.

Related articles

$HCAMed

Uninsured patients rise sharply, hospitals report, citing Obamacare cuts | Chattanooga Times Free Press

More and more uninsured patients are showing up in hospital emergency rooms and clinics, having lost their coverage under the Affordable Care Act. Executives running some of the biggest hospital systems, including large for-profit chains spanning many states, expressed concern over the unexpectedly sharp rise in uninsured patients and the costs associated with treating them.

$THCMedAI 8/10

Tenet raises 2026 outlook after weathering ACA headwinds

Tenet Healthcare raised 2026 guidance after Q2 headwinds on Affordable Care Act exchanges. The company now expects adjusted EBITDA of $4.8B to $5.0B, up from $4.5B to $4.8B. Q2 net income rose to $826M on $5.6B revenue, though ACA revenue fell $65M as ACA admissions declined.

$THCHighAI 9/10

Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook

Tenet Healthcare (THC) reported Q2 2026 adjusted EPS of $6.12, 50% above the Zacks Consensus, with net operating revenues up 6.8% to $5.63B. Adjusted net income rose 39.3% to $514M. The company raised 2026 guidance for revenue, adjusted EBITDA, and adjusted EPS, and authorized a $2B share repurchase increase.

$THCMedAI 8/10

Why Tenet Healthcare Stock Is Soaring Today

Tenet Healthcare (THC) shares rose after the company reported fiscal Q2 results and raised 2026 guidance. For the quarter ended in June, revenue was $5.63B and adjusted EPS was $6.12, both above year-ago figures and analyst estimates ($5.43B revenue, $4.26 EPS). 2026 revenue guidance increased to $21.9B-$22.5B and adjusted EBITDA to $4.83B-$5.03B.